Biological Information

Background Information:

The G protein-coupled receptors ETA and ETB are both endothelin receptors whose activation results in the elevation of intracellular-free calcium. ETA is expressed primarily on vascular smooth muscles, mediating vasoconstriction and sodium retention, leading to increased blood pressure. ETB is expressed predominantly on the endothelial surface of vessels, mediating vasodilatation through the production of nitric oxide and prostacyclin. ETA activation has damaging effects on preeclampsia, heart failure, pulmonary hypertension, and kidney natriuresis. Endothelin-receptor antagonists (ERA) can improve exercise capacity, hemodynamics, symptoms, and right ventricle function as an important treatment of hypertension. The selective blockade of ETA blocks only the harmful vasoconstriction effects of ETA but maintains the potential beneficial effects mediated by ETB (vasodilatation and endothelin clearance).

No. of Assays on Panel:

2

Assays on Panel:

Family

GPCR

Name

Item

311010-0

Protein

ETA

Organism

Human

Assay Sub Type

Cell Based

Family

GPCR

Name

Item

311010-1

Protein

ETA

Organism

Human

Assay Sub Type

Cell Based

Family:

GPCR

Sub Family:

Endothelin

Class:

Class A

Protein Name:

ETA

Uniprot Number:

P25101

Protein Aliases:

ET-A|ET-AR

Gene Name:

EDNRA

Gene ID:

1909

Accession Number:

S63938

Organism:

Human

Construct Details:

Recombinant

Cell Type:

Chem-1

Assay Information

Assay Type:

Functional

Assay Sub Type:

Cell Based

Functional Mode:

Agonist & Antagonist

Detection Method:

TR-FRET

Measured Response:

Fluorescence

Testing Information

Procedure Summary:

Human recombinant endothelin ETA receptors expressed in Chem-1 cells are used. Test compound and/or vehicle is incubated with the cells (1.5 x 10^6 /ml) in stimulation buffer of IP1 Tb kit for 30 minutes at 37°C. Test compound-induced increase of fluorescence by 50 percent or more (≥50%) relative to the 1 μM endothelin-1 response indicates possible ETA receptor agonist activity. Test compound-induced inhibition of 1 nM endothelin-1 induced increase of fluorescence response by 50 percent or more (≥50%) indicates receptor antagonist activity.

Incubation:

30 min at 37°C

Control Inhibitor:

BQ-610

Control Activator:

Endothelin-1

Criteria For Significance:

≥ 50% increase in IP-one relative to Endothelin-1 response, ≥ 50% inhibition of Endothelin-1-induced response

Test Concentration / Dose:

Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM

Test Sample Requirements:

75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)

Minimum Order Quantity:

16

Turnaround Time

Standard:

20 Business Days

Reference Compound Data

PubChem ID

123905

Name

BQ-610

Measurement

0.0024μM - IC50

PubChem ID

16219006

Name

BQ-123

Measurement

0.037μM - IC50

PubChem ID

44284481

Name

Endothelin-1

Measurement

0.00025μM - EC50

PubChem ID

101675604

Name

BQ-788

Measurement

0.98μM - IC50

Clinical Relevance

Therapeutic Area:

Cardiovascular

Adverse / Beneficial Action:

ETA receptor agonism may cause vasoconstriction, positive inotropy, and facilitate cell proliferation (e.g., smooth muscle, mesangial cells).

Additional Information

Brand:

LeadHunter

Testing Location:

Taiwan - Taipei